1.	Aromatase Inhibitor Clinical Trial Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 40 to 70 Sponsor: NIGMS Protocol IDs: 0412-14, UO1-GM61373-06, NCT00228956
2.	Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 45 Sponsor: Other Protocol IDs: 0501-37, NCT00352872
3.	Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 26658, NCT00872859
4.	A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO# 08-1373, NCT00900744
5.	Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-09-14B, NCT00984269
6.	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 20050113, NCT00243685
7.	Phase II/III Randomized Study of Neoadjuvant Therapy Comprising Exemestane Versus Letrozole Versus Anastrozole in Postmenopausal Women With Estrogen Receptor Positive Stage II or III Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: Postmenopausal Sponsor: NCI Protocol IDs: ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
8.	Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: 0120070323, NCT00698971
9.	Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0221, S0221, NCT00070564
10.	Phase III Randomized Study of Adjuvant Chemotherapy in Women With Radically Resected Loco-Regional Relapsed Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: IBCSG-27-02, BIG-1-02, EU-20320, NCT00074152, NSABP-B-37, EUDRACT-2005-001484-64
11.	A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DOXIL-BCA-3001, NCT00091442
12.	Phase III Randomized Study of Adjuvant Zoledronate Versus Clodronate Versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0307, NCCTG-SWOG-S0307, ECOG-SWOG-S0307, NSABP-SWOG-S0307, CALGB-SWOG-S0307, CAN-NCIC-SWOG-S0307, S0307, NCT00127205
13.	Phase III Randomized Study of Fulvestrant With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage III or IV Hormone Receptor-Positive Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40302, NCT00390455
14.	A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181114, NCT00428220
15.	Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer Phase: Phase III Type: Behavioral study, Supportive care, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: OCOG-2007-LISA, NCT00463489
16.	ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF106708, BIG 2-06/N063D/MAC13, NCT00490139
17.	A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOC4129g, WO20698, NCT00567190
18.	Phase III Randomized Study of Adjuvant Combination Chemotherapy Followed By Docetaxel Versus Ixabepilone in Women With Completely Resected Nonmetastatic, Poor-Prognosis Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: FNCLCC-PACS-08/0610, FNCLCC-PACS 08/0610 – TavIx, EU-20804, FNCLCC-Tavlx, BMS-FNCLCC-PACS-08/0610, AMGEN-FNCLCC-PACS-08/0610, NCT00630032
19.	BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NSABP B-44-I, CIRG (TRIO) 011, Roche BO20906, BETH, NCT00625898
20.	Phase III Study of Docetaxel + IMC-1121B or Placebo in Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP12-0606, TRI0-CIRG-012, TRI0-012, EUDRACT Number: 2008-001727-65, NCT00703326
21.	Phase III Randomized Study of Neoadjuvant Paclitaxel in Combination With Trastuzumab (Herceptin®) and/or Lapatinib Ditosylate in Patients With HER2-Positive Resectable Stage II or III Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40601, CALGB 40601, NCT00770809
22.	Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3144A2-3003, NCT00777101
23.	An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TDM4370g, 2008-005 713-22, NCT00829166
24.	Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001Y2301, EUDRACT Number: 2008-008698-69, NCT00863655
25.	Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001J2301, EUDRACT Number: 2008-006556-21, NCT00876395